Alzprotect
Biopharmaceutical company which develop new bioactive molecules for the treatment of neurodegenerative diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
€56—84m (Dealroom.co estimates Jan 2018.)
Company register number 501096838
Loos Hauts-de-France (HQ)
Financials
Estimates*
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|
| EBITDA | (2.1m) | (1.6m) | (1.6m) | (3.4m) | (3.2m) | (2.8m) |
| Profit | (1.7m) | (1.3m) | (1.3m) | (2.6m) | (2.5m) | (2.1m) |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Seed | ||
€2.0m | Series A | ||
€14.0m | Series B | ||
* | $340k | Grant | |
| Total Funding | €16.3m | ||
Related Content
Recent News about Alzprotect
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.